Q-omics provides the consensus-scored NOXRED1 profile across patient tissues and cancer cell-line models. NOXRED1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, NOXRED1 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, NOXRED1 RNA expression shows 20,622 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, THCA, and ACC as cancer lineages where NOXRED1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NOXRED1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NOXRED1 survival associations across molecular data types. NOXRED1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NOXRED1 RNA expression–survival associations across cancer types. High NOXRED1 expression shows unfavorable associations in KICH, LGG and LIHC, but favorable associations in BRCA, PAAD and MESO. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify KICH as the clearest survival context for NOXRED1 RNA expression.
This table summarizes NOXRED1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for NOXRED1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NOXRED1 shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, CHOL, BLCA and STAD. The THCA box plot shows higher NOXRED1 RNA expression in normal versus tumor tissue (log2 FC = −0.552, t-test p < 0.001).
This table shows molecular features associated with NOXRED1 in patient tissues and cancer cell lines. In patient samples, NOXRED1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, NOXRED1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and SOFT_TISSUE.
